In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
After finishing at $19.73 in the prior trading day, Adma Biologics Inc (NASDAQ: ADMA) closed at $19.17, down -2.84%. In other words, the price has decreased by -$2.84 from its previous closing price. On the day, 3.98 million shares were traded. ADMA stock price reached its highest trading level at $19.88 during the session, while it also had its lowest trading level at $18.33.
Ratios:
Our goal is to gain a better understanding of ADMA by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 74.33 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 112.02. For the most recent quarter (mrq), Quick Ratio is recorded 3.65 and its Current Ratio is at 7.13. In the meantime, Its Debt-to-Equity ratio is 0.19 whereas as Long-Term Debt/Eq ratio is at 0.18.
On October 13, 2022, Mizuho started tracking the stock assigning a Buy rating and target price of $5.
Raymond James Upgraded its Outperform to Strong Buy on November 11, 2021, while the target price for the stock was maintained at $5.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 15 ’25 when Grossman Adam S sold 21,000 shares for $19.79 per share. The transaction valued at 415,590 led to the insider holds 2,007,850 shares of the business.
Grossman Adam S sold 21,000 shares of ADMA for $336,000 on Nov 19 ’25. The President and CEO now owns 2,013,850 shares after completing the transaction at $16.00 per share. On Oct 24 ’25, another insider, Grossman Adam S, who serves as the President and CEO of the company, sold 21,000 shares for $16.00 each. As a result, the insider received 336,000 and left with 2,019,850 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ADMA now has a Market Capitalization of 4574551040 and an Enterprise Value of 4584155136. As of this moment, Adma’s Price-to-Earnings (P/E) ratio for their current fiscal year is 22.51, and their Forward P/E ratio for the next fiscal year is 22.16. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.57. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.34 while its Price-to-Book (P/B) ratio in mrq is 10.60. Its current Enterprise Value per Revenue stands at 9.383 whereas that against EBITDA is 26.194.
Stock Price History:
The Beta on a monthly basis for ADMA is 0.46, which has changed by 0.11468923 over the last 52 weeks, in comparison to a change of 0.16081822 over the same period for the S&P500. Over the past 52 weeks, ADMA has reached a high of $25.67, while it has fallen to a 52-week low of $13.50. The 50-Day Moving Average of the stock is 15.59%, while the 200-Day Moving Average is calculated to be 5.78%.
Shares Statistics:
The stock has traded on average 3.43M shares per day over the past 3-months and 2507080 shares per day over the last 10 days, according to various share statistics. A total of 238.33M shares are outstanding, with a floating share count of 229.91M. Insiders hold about 3.40% of the company’s shares, while institutions hold 92.78% stake in the company. Shares short for ADMA as of 1764288000 were 18563031 with a Short Ratio of 5.42, compared to 1761868800 on 16649924. Therefore, it implies a Short% of Shares Outstanding of 18563031 and a Short% of Float of 9.58.
Earnings Estimates
Investors are keenly observing as 1.0 analysts analyze and rate. The current performance of Adma Biologics Inc (ADMA) in the stock market.The consensus estimate for the next quarter is $0.2, with high estimates of $0.2 and low estimates of $0.2.
Analysts are recommending an EPS of between $0.6 and $0.6 for the fiscal current year, implying an average EPS of $0.6. EPS for the following year is $0.94, with 1.0 analysts recommending between $0.94 and $0.94.
Revenue Estimates
2 analysts predict $139.85M in revenue for. The current quarter. It ranges from a high estimate of $140.3M to a low estimate of $139.4M. As of. The current estimate, Adma Biologics Inc’s year-ago sales were $117.55MFor the next quarter, 2 analysts are estimating revenue of $145.35M. There is a high estimate of $149M for the next quarter, whereas the lowest estimate is $141.7M.
A total of 2 analysts have provided revenue estimates for ADMA’s current fiscal year. The highest revenue estimate was $511.3M, while the lowest revenue estimate was $510.4M, resulting in an average revenue estimate of $510.85M. In the same quarter a year ago, actual revenue was $426.45MBased on 2 analysts’ estimates, the company’s revenue will be $631.85M in the next fiscal year. The high estimate is $632.5M and the low estimate is $631.2M.
